Altria Group, Inc. (MO)
Best Stock to Buy Right Now: Altria Group vs. British American Tobacco
Altria Group and British American Tobacco can protect your portfolio during a market downturn. Both stocks can also deliver huge dividend yields.
3 Ticking Time Bombs in Your Portfolio to Sell Now
Identifying potential risks in your portfolio is crucial for long-term success. As of July 2024, several stocks exhibit significant warning signs suggesting they might be stocks to sell now.
3 Reasons to Buy Altria Stock Like There's No Tomorrow
It's not for everyone, but Altria stock offers double-digit investment returns today. Next-generation products are gaining market share.
Can These 2 Ultra-High-Yield Dividend Stocks Outperform the S&P 500 in 2024?
Altria and AT&T have both been on a tear during the first six months of 2024. Meanwhile, the S&P 500 has crossed over into premium valuation territory, buoyed by Nvidia's incredible run.
Altria (MO) Up 11% in 3 Months: Is There More Room for Growth?
Altria (MO) is benefiting from its focus on expanding smoke-free alternatives and strong pricing power amid low cigarette volumes.
Where Will Altria Stock Be in 5 Years?
Altria Group stock has lagged the market in recent years. However, several factors point to a bright future.
Altria Group: Buy, Sell, or Hold?
Altria stock has lagged the market in recent years. Yet shares are undeniably cheap, sporting an 8.6% dividend yield.
Can NJOY Help Propel Altria Group Stock Higher?
The FDA recently authorized the sale of four menthol-flavored NJOY products from Altria. NJOY could help the company return to revenue growth.
Want $1,000 in Super-Safe Dividend Income? Buy $11,862 of This Ultra-High-Dividend Yield Stock
Altria Group's cigarette volumes are declining, but price increases are helping to maintain profits. The company has plenty of room to maintain or grow its dividend payments.
Altria Group, Inc. (MO) Is a Trending Stock: Facts to Know Before Betting on It
Zacks.com users have recently been watching Altria (MO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Altria seeks FDA marketing order for oral nicotine pouch products
Tobacco giant Altria said on Wednesday it had submitted Premarket Tobacco Product Applications (PMTAs) to the U.S. Food and Drug Administration for its on! Plus oral nicotine pouch products.
Altria: 8.5% Dividend Looks More Attractive In An Overheated Stock Market
Altria Group is facing several challenges which are reflected in its rock-bottom valuation, but it has some core strengths which make the stock a Buy. The biggest issue is the secular decline in shipment volume of its smokeable products, which declined by a staggering 10 percentage points YoY in the recent quarter. However, the company is making up for these lost volumes with price increases, and the worst-case scenario for volume decline is also not too bad for the long-term EPS trajectory.
